AnaptysBio (NASDAQ: ANAB) — Perfil da empresa, notícias e dados financeiros
AnaptysBio advances antibody therapies for inflammation and cancer, leveraging its proprietary hypermutation platform.
AnaptysBio
AnaptysBio (NASDAQ:ANAB) is a biotechnology company focused on advancing a pipeline of innovative antibody therapies aimed at addressing significant unmet medical needs in inflammation, immuno-oncology, and other diseases. Operating out of its base, the company leverages its proprietary somatic hypermutation (SHM) platform to discover and develop a range of novel antibodies. AnaptysBio's key projects include treatments for conditions such as severe inflammatory diseases and cancer, with several candidates currently undergoing clinical trials. The company's objectives center on bringing transformative therapeutic options to patients through meticulous research and development, while continuously expanding its portfolio of antibody therapeutics to improve patient outcomes in areas with critical healthcare needs.
Resumo
Operações
Produtos e/ou serviços de AnaptysBio
- Immunotherapy drugs marketed to treat various inflammatory diseases including psoriasis, rheumatoid arthritis, and asthma.
- Custom antibody development services leveraging their proprietary platforms for pharmaceutical and biotechnology companies.
- Collaboration with large pharmaceutical companies to co-develop and co-commercialize novel immunotherapy treatments.
- Pipeline of experimental therapies aimed at treating autoimmune disorders through targeted immune modulation.
- Research and development in cancer immunotherapy, focusing on enhancing the efficacy of existing treatments.
- Advancement of bi-specific antibody technologies designed to address complex disease targets not amenable to traditional antibody approaches.
equipe executiva do AnaptysBio
- Daniel R. FagaPresident, CEO & Director
- Christopher M. MurphyChief Financial Officer
- Beth MuellerSenior Vice President of Human Resources
- Benjamin StoneChief Business Officer
Principais indicadores financeiros
Resultados divulgados pela AnaptysBio, em USD.
- Cap. de mercado
- 1,5 bi
- Receita (TTM)
- 106,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.0
- Dividend yield
- —
- Margem de lucro
- 247.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 234,6 mi | 47,9 mi | -13,2 mi | |
| 91,3 mi | -114,9 mi | -145,2 mi | |
| 17,2 mi | -164,4 mi | -163,6 mi | |
| 10,3 mi | -115,2 mi | -128,7 mi |